🩺What is Disseminated Intravascular Coagulation?
The ISTH (International Society on Thrombosis and Haemostasis) DIC scoring system was established in 2001 to provide an objective, standardized method for diagnosing overt DIC. It uses four readily available laboratory parameters: platelet count, D-dimer/fibrin degradation products, PT prolongation, and fibrinogen level. A score of 5 or higher indicates overt DIC, which is associated with increased mortality and requires prompt management of the underlying condition.
📊Clinical Assessment & Risk Scoring
Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Disseminated Intravascular Coagulation:
ISTH DIC Score — Disseminated Intravascular Coagulation
The ISTH DIC score is an objective diagnostic tool for overt disseminated intravascular coagulation (DIC), developed by the International Society on Thrombosis and Haemostasis.
WHO Bleeding Scale for Cancer/Oncology
The World Health Organization (WHO) Bleeding Scale is a standardized 5-grade adverse event classification system used to assess and document bleeding severity in patients with cancer, hematologic malignancies, and chemotherapy-induced thrombocytopenia.
🧬Diagnostic Logic & Scoring Breakdown
The ISTH DIC score is calculated by summing points from four laboratory parameters. Platelet count: >100 (0 pts), 50-100 (1 pt), <50 (2 pts). D-dimer or fibrin degradation products: no increase (0 pts), moderate increase (2 pts), strong increase (3 pts). PT prolongation (compared to normal): <3 sec (0 pts), 3-6 sec (1 pt), >6 sec (2 pts). Fibrinogen: >1.0 g/L (0 pts), ≤1.0 g/L (1 pt). Total score 0-8. Score ≥5 indicates overt DIC with high specificity. The test should be repeated daily or as clinically indicated since DIC is a dynamic condition.
📢Clinical Significance & Implications
The ISTH DIC score is the current gold standard for diagnosing overt DIC, endorsed by the International Society on Thrombosis and Haemostasis. A score ≥5 has a specificity of 97% and sensitivity of 91% for DIC. Early diagnosis is critical, as DIC carries a mortality rate of 30-50% depending on the underlying condition.
💡 Clinical Assessment Scenario Example
A 65-year-old patient with septic shock presents with thrombocytopenia (platelets 45), elevated D-dimer (strong increase), PT prolonged 5 sec, and fibrinogen 0.8 g/L. Score: Platelets <50 (2), D-dimer strong (3), PT 3-6 sec (1), Fibrinogen <1.0 (1) = Total 7/8. Overt DIC confirmed.
💊Common Medications & Interventions
The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Disseminated Intravascular Coagulation:
⚠️Clinical Assessment Pitfalls
❌ Mistake: Using the ISTH DIC score as a screening tool in all hospitalized patients
✅ Correction: The ISTH DIC score should only be applied to patients with an underlying condition known to be associated with DIC (sepsis, trauma, malignancy, obstetrical complications). It is not a screening tool for unselected populations.
❌ Mistake: Using platelet count thresholds inconsistently due to different reference ranges
✅ Correction: Use consistent thresholds: >100 x10^9/L = 0 pts, 50-100 = 1 pt, <50 = 2 pts, regardless of the laboratory reference range.
❌ Mistake: Assigning Grade 1 for any visible bleeding regardless of severity
✅ Correction: Grade 1 is specifically for mild, self-limited bleeding manifestations. If the patient has melena or hematuria, this is Grade 2 or higher regardless of whether transfusion is needed. The key distinction is clinical significance: petechiae and ecchymosis are Grade 1; internal bleeding such as melena or hemoptysis is at least Grade 2.
❌ Mistake: Confusing the WHO Bleeding Scale with the ISTH BAT or CTCAE grading systems
✅ Correction: The WHO Bleeding Scale is a 5-grade global assessment (0-4) focused on bleeding severity and transfusion need. The ISTH Bleeding Assessment Tool (BAT) is a detailed questionnaire for bleeding disorders like von Willebrand disease and hemophilia. CTCAE v5.0 provides organ-specific bleeding grading (e.g., CNS hemorrhage Grade 1-5) that parallels WHO grades but is more granular. The WHO scale remains the preferred tool for rapid clinical assessment in oncology/hematology.
🚑When to Seek Medical Attention
This reference supports clinical assessment of Disseminated Intravascular Coagulation; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.
❓Frequently Asked Questions
Q: What is the difference between overt and non-overt DIC?
Overt DIC (score ≥5) refers to established, clinically significant DIC where the hemostatic system is clearly decompensated. Non-overt DIC (score <5) refers to a compensated or early state where laboratory abnormalities are present but do not meet the threshold for overt DIC. The ISTH recommends serial assessments to detect progression.
Q: How often should the ISTH DIC score be repeated?
The ISTH recommends repeating the score daily for patients with ongoing risk factors (sepsis, trauma, etc.). More frequent testing may be appropriate in rapidly changing clinical situations. A single negative score does not rule out DIC, and a positive score should trigger immediate management.
Q: What is the difference between WHO Grade 1 and Grade 2 bleeding?
The distinction lies in clinical significance. Grade 1 bleeding involves minor, self-limited manifestations such as petechiae (<3 mm pinpoint hemorrhagic spots), ecchymosis (bruises), occult (microscopic) blood in stool or urine, and mild epistaxis lasting less than 1 hour. These findings do not cause clinically significant blood loss or require intervention beyond basic monitoring. Grade 2 bleeding involves clinically evident blood loss visible to the patient or physician — melena (black tarry stools), hematemesis (vomiting blood), gross hematuria (visible red urine), hemoptysis (coughing blood), or hematochezia (rectal bleeding). While these events are more concerning, they do not cause hemodynamic instability or require blood transfusion. The presence of any Grade 2 criterion automatically upgrades the overall bleeding grade to at least 2, even if Grade 1 findings are also present.
Q: When should platelet transfusion be given based on WHO bleeding grade?
Platelet transfusion decisions integrate bleeding grade with platelet count, clinical context, and patient factors. General guidelines: (1) Prophylactic transfusion at platelet count ≤10 × 10⁹/L for stable patients without bleeding (Grade 0). (2) Therapeutic transfusion for Grade 1 bleeding if platelet count ≤20 × 10⁹/L. (3) Therapeutic transfusion for Grade 2 bleeding if platelet count ≤30 × 10⁹/L. (4) For Grade 3-4 bleeding, maintain platelet count >50 × 10⁹/L (and >100 × 10⁹/L for intracranial hemorrhage). These thresholds may be higher for patients undergoing invasive procedures or with active bleeding. Always consult current AABB and ASCO guidelines as recommendations evolve.
📚Evidence-Based References
Medically Reviewed By
Dr. Mahmoud El-Sayed
MD, MSc | Hematology
Dr. Mahmoud El-Sayed is a consultant hematologist with expertise in hemostasis, thrombosis, and coagulation disorders.